ABSTRACT
One of the more recent findings concerning von Willebrand disease (VWD) is that a shorter von Willebrand factor (VWF) survival either decides or modulates the VWD phenotype by downregulating circulating VWF levels. VWF survival is currently investigated with the desmopressin (DDAVP) test, a time-consuming strategy enabling the main pharmacokinetic parameters (e.g., VWF half-life elimination time and clearance) to be defined. An alternative now available involves assaying the VWF propeptide (VWFpp) in single steady-state blood samples, which reportedly increases as VWF survival decreases. This article demonstrates how measuring VWFpp and calculating the VWFpp-to-VWF:antigen ratio (VWFpp ratio) are good alternatives to DDAVP for investigating VWF survival. In type 1 VWD, the VWFpp ratio has been found normal in patients with pure quantitative VWF defects, markedly increased in cases with an isolated decline in VWF survival, and more or less increased in patients with both quantitative defects and a shorter VWF survival. The same applies to type 2B VWD, which is characterized by an increased VWFpp ratio and a shorter VWF survival, with values that appear inversely related. Exploring VWF half-life by assaying VWFpp is useful not only for the more precise characterization of VWD but also for defining its most appropriate treatment.
KEYWORDS
von Willebrand factor -
von Willebrand disease - VWF propeptide - VWFpp ratio - VWF half-life
REFERENCES
-
1
Sadler JE.
Biochemistry and genetics of von Willebrand factor.
Annu Rev Biochem.
1998;
67
395-424
-
2
Ruggeri ZM.
von Willebrand factor, platelets and endothelial cell interactions.
J Thromb Haemost.
2003;
1
(7)
1335-1342
-
3
Ruggeri ZM, Zimmerman TS.
von Willebrand factor and von Willebrand disease.
Blood.
1987;
70
(4)
895-904
-
4
Wagner DD.
Cell biology of von Willebrand factor.
Annu Rev Cell Biol.
1990;
6
217-246
-
5
Hoyer LW, Shainoff JR.
Factor VIII-related protein circulates in normal human plasma as high molecular weight multimers.
Blood.
1980;
55
(6)
1056-1059
-
6
Gralnick HR, Williams SB, Morisato DK.
Effect of multimeric structure of the factor VIII/von Willebrand factor protein on binding to platelets.
Blood.
1981;
58
(2)
387-397
-
7
Voorberg J, Fontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H.
Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids.
J Cell Biol.
1991;
113
(1)
195-205
-
8
Wagner DD, Marder VJ.
Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localization.
J Cell Biol.
1984;
99
(6)
2123-2130
-
9
Verweij CL, Hart M, Pannekoek H.
Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation.
EMBO J.
1987;
6
(10)
2885-2890
-
10
Mayadas TN, Wagner DD.
Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly.
Proc Natl Acad Sci U S A.
1992;
89
(8)
3531-3535
-
11
Sadler JE.
von Willebrand factor assembly and secretion.
J Thromb Haemost.
2009;
7
(Suppl 1)
24-27
-
12
Purvis AR, Sadler JE.
A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization.
J Biol Chem.
2004;
279
(48)
49982-49988
-
13
Purvis AR, Gross J, Dang LT et al..
Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.
Proc Natl Acad Sci U S A.
2007;
104
(40)
15647-15652
-
14
Wise RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH.
The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers.
Cell.
1988;
52
(2)
229-236
-
15
Wagner DD, Fay PJ, Sporn LA, Sinha S, Lawrence SO, Marder VJ.
Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.
Proc Natl Acad Sci U S A.
1987;
84
(7)
1955-1959
-
16
Vischer UM, Wagner DD.
von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies.
Blood.
1994;
83
(12)
3536-3544
-
17
Sporn LA, Marder VJ, Wagner DD.
Inducible secretion of large, biologically potent von Willebrand factor multimers.
Cell.
1986;
46
(2)
185-190
-
18
Borchiellini A, Fijnvandraat K, ten Cate JW et al..
Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans.
Blood.
1996;
88
(8)
2951-2958
-
19
Usui T, Takagi J, Saito Y.
Propolypeptide of von Willebrand factor serves as a substrate for factor XIIIa and is cross-linked to laminin.
J Biol Chem.
1993;
268
(17)
12311-12316
-
20
Takagi J, Sekiya F, Kasahara K, Inada Y, Saito Y.
Inhibition of platelet-collagen interaction by propolypeptide of von Willebrand factor.
J Biol Chem.
1989;
264
(11)
6017-6020
-
21
Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ.
The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII.
J Biol Chem.
1991;
266
(32)
21948-21955
-
22
Casonato A, Sartorello F, Cattini MG et al..
An Arg760Cys mutation in the consensus sequence of the von Willebrand factor propeptide cleavage site is responsible for a new von Willebrand disease variant.
Blood.
2003;
101
(1)
151-156
-
23
van Mourik JA, Boertjes R, Huisveld IA et al..
von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation.
Blood.
1999;
94
(1)
179-185
-
24
Casonato A, Pontara E, Sartorello F et al..
Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
Blood.
2002;
99
(1)
180-184
-
25
Haberichter SL, Balistreri M, Christopherson P et al..
Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival.
Blood.
2006;
108
(10)
3344-3351
-
26
Haberichter SL, Castaman G, Budde U et al..
Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).
Blood.
2008;
111
(10)
4979-4985
-
27
Casonato A, Gallinaro L, Cattini MG et al..
Type 1 von Willebrand disease due to reduced von Willebrand factor synthesis and/or survival: observations from a case series.
Transl Res.
2010;
155
(4)
200-208
-
28
Nossent AY, VAN Marion V, VAN Tilburg NH et al..
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.
J Thromb Haemost.
2006;
4
(12)
2556-2562
-
29
Gill JC, Endres-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR.
The effect of ABO blood group on the diagnosis of von Willebrand disease.
Blood.
1987;
69
(6)
1691-1695
-
30
Gallinaro L, Cattini MG, Sztukowska M et al..
A shorter von Willebrand factor survival in O blood group explains how ABO determinants influence plasma von Willebrand factor.
Blood.
2008;
111
3540-3545
-
31
Sadler JE, Budde U, Eikenboom JC Working Party on von Willebrand Disease Classification et al.
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor.
J Thromb Haemost.
2006;
4
(10)
2103-2114
-
32
Gézsi A, Budde U, Deák I et al..
Accelerated clearance alone explains ultra-large multimers in von Willebrand disease Vicenza.
J Thromb Haemost.
2010;
8
(6)
1273-1280
-
33
Sztukowska M, Gallinaro L, Cattini MG et al..
von Willebrand factor propeptide makes it easy to identify the shorter von Willebrand factor survival in patients with type 1 and type Vicenza von Willebrand disease.
Br J Haematol.
2008;
143
(1)
107-114
-
34
de Romeuf C, Mazurier C.
Comparison between von Willebrand factor (VWF) and VWF antigen II in normal individuals and patients with von Willebrand disease.
Thromb Haemost.
1998;
80
(1)
37-41
-
35
Millar CM, Riddell AF, Brown SA et al..
Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.
Thromb Haemost.
2008;
99
(5)
916-924
-
36
Casonato A, Gallinaro L, Cattini MG et al..
Reduced survival of type 2B von Willebrand factor, irrespective of large multimer representation or thrombocytopenia.
Haematologica.
2010;
95
(8)
1366-1372
Alessandra CasonatoPh.D.
Department of Cardiologic, Thoracic and Vascular Sciences
Via Ospedale Civile 105, Padua, Italy
Email: sandra.casonato@unipd.it
